

INTERNATIONAL COLLABORATORS

We have also engaged international collaborators from critical care trials groups in Switzerland, the United Kingdom (UK), Saudi Arabia, Australia and New Zealand. Our Australia, New Zealand, Switzerland, and Saudi Arabia collaborators have all confirmed similar antibiotic treatment durations for bacteremia in their ICU patients. In contrast our UK collaborators have applied our electronic case report form, and detected much shorter treatment durations in their ICUs (median 7days, IQR 2-10 days), which are in keeping with one prior observational study from the UK. Like the longer prevailing treatment durations in Canada, the shorter treatment durations in the UK are not grounded in RCT evidence. International practice variation highlights the urgency, importance and equipoise for this trial testing whether 7 day treatment is non-inferior to 14 day treatment for bacteremia. To improve trial efficiency, increase global generalizability, and augment the precision of survival estimates, our international collaborators will seek funding to add additional international sites to the Canadian-led trial.

Investigator	Hospital	City	Country
Dr. Shay McGuinness	Auckland City Hospital	Auckland	New Zealand
Dr. Colin McArthur	Auckland City Hospital	Auckland	New Zealand
Dr. Rachael Parke	Auckland City Hospital	Auckland	New Zealand
Dr. Steve Webb	Royal Prince Perth Hospital	Western Australia	Australia
Dr. Yahya Shehabi	University of New South Wales Clinical School	Randwick	Australia
Dr. Philippe Eggimann	Hospitalier Universitaire Vaudois Lausanne	Lausanne	Switzerland
Dr. Jean-Luc Pagani	Hospitalier Universitaire Vaudois Lausanne	Lausanne	Switzerland
Dr. Yok Ai Que	Hospitalier Universitaire Vaudois Lausanne	Lausanne	Switzerland
Dr. Yaseen Arabi	King Abdulaziz Medical City	Riyadh	Saudi Arabia
Dr. Tim Walsh	University of Edinburgh	Scotland	UK
Dr. Paul Dark	Salford Royal NHS Foundation trust	Salford	UK
Dr. Thomas Hellyer	Newcastle University	Newcastle	UK